

FORM PTO 1390  
(REV 5-93)

US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.  
2000\_1561ATRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 USC 371U.S. APPLICATION NO.  
(if known, see 37 CFR 1.52)

09/700843

International Application No.  
PCT/JP99/02683International Filing Date  
May 21, 1999Priority Date Claimed  
May 22, 1998

## Title of Invention

A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR

## Applicant(s) For DO/EO/US

Tamas LUKACSOVICH, Zoltan ASZTALOS, Daisuke YAMAMOTO and Wakae AWANO

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☐ This is an express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 USC 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau). **ATTACHMENT A**
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 USC 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. ☒ An unexecuted oath or declaration of the inventor(s) (35 USC 371(c)(4)). **ATTACHMENT B**
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment. **ATTACHMENT C**  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. (if known, see 37 CFR 1.51)  
NEW

09/700843

INTERNATIONAL APPLICATION NO.

ATTORNEY DOCKET NO.  
2000 1561A17. ☒ The following fees are submitted**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

- ☒ Search Report has been prepared by the EPO or JPO . . . . . \$860.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) . . . . . \$690.00
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482)  
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . . . . \$700.00
- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . \$1000.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(2)-33(4) . . . . . \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the  
earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims

Number Filed

Number Extra

Rate

Total Claims

- 20 =

X \$18.00

\$

Independent Claims

- 3 =

X \$80.00

\$

Multiple dependent claim(s) (if applicable)

+ \$270.00

\$

**TOTAL OF ABOVE CALCULATIONS =**

\$860.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also  
be filed. (Note 37 CFR 1.9, 1.27, 1.28)

\$

**SUBTOTAL =**

\$860.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from  
the earliest claimed priority date (37 CFR 1.492(f)).

+

\$

**TOTAL NATIONAL FEE =**

\$860.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (\$40 per property).

+

\$

**TOTAL FEES ENCLOSED =**

\$860.00

Amount to be  
refunded:

\$

charged:

\$

09/700843

532 Rec'd PCT/PTO 21 NOV 2000

- a. ☒ A check in the amount of \$860.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 23-0975 in the amount of \$\_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

WENDEROTH, LIND & PONACK  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006

Telephone: (202) 721-8200  
Facsimile: (202) 721-8250

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367

November 21, 2000  
WMC/dlk

Check No. 40835

2000\_1561A

09/700843

532 Rec'd PCT/JP 21 NOV 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Tamas LUKACSOVICH et al. : Attn: BOX PCT  
Serial No. NEW : Docket No. 2000-1561A  
Filed November 21, 2000 :

A VECTOR FOR GENE TRAP, AND A METHOD FOR  
GENE TRAPPING BY USING THE VECTOR  
[Corresponding to PCT/JP99/02683  
Filed May 21, 1999]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, immediately after the title, please insert:

-- This application is a 371 of PCT/JP99/02683 filed May 21, 1999. --

IN THE CLAIMS

Claim 3, line 1, delete "or 2".  
Claim 5, line 1, delete "or 2".  
Claim 6, line 1, delete "or 2".  
Claim 7, line 1, change "any one of claims 1-6" to -- claim 1 --.  
Claim 8, line 1, change "any one of claims 1-7" to -- claim 1 --.  
Claim 12, line 1, delete "or 11".

ATTACHMENT C

Claim 13, line 1, delete "or 11".  
Claim 14, line 1, change "any one of claims 10 to 14" to -- claim 10 --.  
Claim 15, line 1, change "any one of claims 10 to 15" to -- claim 10 --.  
Claim 18, line 1, delete "or 17".  
Claim 19, line 1, change "any one of claims 16 to 18" to -- claim 16 --.

**REMARKS**

The foregoing amendments are effected to amend the specification to reflect the 371 status. In addition, the multiple dependencies of the claims have been eliminated to remove the improper multiple dependencies and to reduce the PTO filing fee.

Favorable action on the merits is solicited.

Respectfully submitted,

Tamas LUKACSOVICH et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C.  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 21, 2000

## Description

### A Vector for Gene Trap, and A Method for Gene Trapping by Using The Vector

5

## Technical Field

The present invention relates to a new vector system to facilitate the cloning and functional analysis of new genes of a fly, *Drosophila melanogaster*, and a method for gene trapping with the vector system.

## Background Art

There are numerous examples for application of gene trapping methods in wide range of living organisms including maize and mouse (Gossler et al., Science, 244:463-465, 1989).

With respect to tools for gene trapping, the application of different types of enhancer trap P-element vectors (Wilson et al., Genes & Development, 3:1301-1313, 1989) for cloning and analyzing trapped genes, as well their use for mosaic analysis with the help of the Gal4/UAS transcription activator system has proven fruitful. However, sometimes the expression pattern of the Gal4 or other reporter gene of the vector construct is affected by enhancers belonging to more than one gene. Similarly, in some cases it is difficult to determine whether the enhancer trap insertion effects the function of one or more of the neighboring genes.

These circumstances altogether with the fact that in some cases the mutant phenotype could be attributed to the



changed expression of a gene with its nearest exon located more than 30 kB apart from the insertion site, can lead in unfortunate cases to an ordeal when it's time to clone and analyze the affected gene.

5 One object of this application is to provide a vector system that includes specifically designed artificial regulatory sequences as well as selection methods for easy screening of positive recombinant lines. More especially, this application intends to provide a vector system of this  
10 invention offering much easier and faster cloning opportunities of the affected gene, compared to the widely used enhancer trap P-element vectors. Another object of this application is to provide easier detection method possibilities of the successful trapping events and much  
15 higher chance to get more characteristic ("functional") expression patterns of the reporter gene because in the contrary with much of the cases with enhancer trap lines, when using the vector system of this invention, the reporter gene expression is influenced only by a single endogenous  
20 transcription unit and effects only the expression of the very same gene.

### Disclosure of Invention

The first invention of this application is a vector for  
25 trapping an unknown gene of *Drosophila melanogaster*, which is a recombinant plasmid comprising the following nucleotide sequences in this order:

- an artificial consensus splicing acceptor site;
- a synthetic "stop/start" sequence;
- 30 a reporter gene;

a drug resistance gene;  
a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and  
a synthetic splicing donor site.

5 One embodiment of the first invention is that the recombinant plasmid is derived from pCasper3.

Other embodiments of the first invention are that the reporter gene is the Gal4 gene, Gal4 DNA binding domain-P53 fusion gene or the Gal4-firefly luciferase fusion gene.

10 Further embodiment of this first invention is that the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene.

More further embodiment of the first invention is that the drug resistance gene is neomycin-phosphotransferase gene  
15 and its promoter is a heatshock promoter.

The second invention of this application is a method for trapping an unknown gene of *Drosophila melanogaster* by using a vector which is a recombinant plasmid comprising the  
20 following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;  
a synthetic "stop/start" sequence;  
a reporter gene;  
a drug resistance gene;  
25 a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and  
a synthetic splicing donor site,

which method comprises the steps of:

(a) introducing the vector into the genome of a white minus  
30 fly;



- (b) selecting primary transformants resistant to a drug;
- (c) crossing the primary transformants with a transposase source strain to force the vector to jump into other locations;
- 5 (d) selecting secondary transformants by picking up the flies having strong eye color,
- (e) crossing the secondary transformants with UAS (Upstream Activator Sequence)-luciferase harboring strain and measuring the reporter gene expression of the resultant flies; and
- 10 (f) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

The third invention of this application is a method for trapping an unknown gene of *Drosophila melanogaster* by using a vector A which is a recombinant plasmid comprising the following nucleotide sequences in this order:

- an artificial consensus splicing acceptor site;
- a synthetic "stop/start" sequence;
- 20 Gal4 DNA binding domain-P53 fusion gene as a reporter gene;
- a drug resistance gene;
- a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and
- a synthetic splicing donor site,

25 and a vector B derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs, which method comprises the steps of:

- (a) introducing each of the vectors A and B into the
- 30 genomes of separate white minus flies;

(b) selecting primary transformants for the vector A which are resistant to the drug, and selecting primary transformants for the vector B which have an eye color;

(c) crossing the primary transformants for the vector A with a transposase source strain to force the vector to jump into other locations;

(d) selecting secondary transformants for the vector A by picking up the flies having strong eye color;

(e) crossing the secondary transformants with the primary transformants for the vector B to obtain flies harboring both the vectors A and B;

(f) crossing the flies obtained in the step (e) with an UAS-luciferase harboring fly strain and measuring the reporter gene expression of the resultant flies after a heatshock treatment; and

(g) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

Embodiments of the second and third inventions are corresponded to the embodiments of the first invention, and they will be more precisely described in the following description.

#### Brief Description of Drawings

Figure 1 shows the schematic map of the vector of this invention, pTrap-hsneo.

Figure 2 shows the schematic map of the vector of this invention, pTrap-G4-p53.

Figure 3 shows the schematic map of the vector of this

invention, pCasperhs-G4-LT.

Figure 4 shows the schematic map of the vector of this invention, pTrap-G4-luc.

Figure 5 shows the shematic drawing of a fly genome to which the vector of this invention is inserted for cloning.

Figure 6 shows the results of sequencing RT-PCR products of aop-Gal4 and m-white-aop fusion mRNAs.

Figure 7 presents pictures of characteristic beta-galactosidase staining patterns in different parts of the fly brain resulted from crossing positive gene trap lines with flies harboring a UAS-lacZ construct.

#### Best Mode for Carrying Out the Invention

A vector construct of the first invention, for example, can be based on the commonly used, P-element transformation vector, pCasper3 (Pirota, Vectors: A survey of molecular cloning vectors and their uses, eds. Rodriguez, R.L. & Denhardt, D.T., Butterworths, Boston. 437-456, 1998) and the convenient Gal4-UAS expression system (Brand and Perrimon, Development, 118:401-415, 1993).

A promoterless Gal4 gene preceded by an artificial consensus splicing acceptor site and a synthetic "stop/start" sequence to govern the read through translation coming from upstream exon(s) of the trapped gene into the proper reading frame of Gal4 was inserted into the polycloning site of pCasper3.

The removal of the whole 3' UTR (untranslated region) sequence of the mini-white gene and replacement by an artificial splicing donor site resulted in a truncated gene without its own poly-adenylation site.

Without a successful gene trapping event this truncated mini-white gene was not expected to confer any eye color, therefore in this invention a heatshock promoter directed neomycin-phosphotransferase (hs-neo) gene for helping selection of primary transformants by antibiotic feeding has been inserted.

Figure 1 shows the schematic map of the gene trap construct (pTrap-hsneo), and SEQ ID No.1 is the complete nucleotide sequence of the vector pTrap-hsneo.

Another gene trap construct, pTrap-G4-p53 (Figure 2) is created by replacing the Gal4 coding sequence of plasmid pTrap-hsneo with a Gal4 DNA binding domain-P53 fusion gene (Clontech, Matchmaker Two Hybrid System, #K1605-1). When this construct coexists in the genome of the same fly with another vector, pCasperhs-G4-LT (Figure 3) containing a heatshock promoter directed Gal4 activator domain-large T antigen (Clontech, Matchmaker Two Hybrid System, #K1605-1) fusion gene, the assembly of a functional Gal4 molecule, through p53-large T antigen interaction, can be regulated by external heatshock.

On this way, the possibility of an intentional temporary control of Gal4 activity became available. In other words the Gal4 expression in a pattern as already determined spatially by the promoter of the trapped gene now can be induced at any desired stage of development by external heatshock.

In order to make the detection of Gal4 expression easier, the Gal4 gene in another construct is replaced with a Gal4-firefly luciferase fusion gene to get pTrap-G4-luc (Figure 4). This artificial gene is coding for a fusion

polypeptide which has preserved both enzymatic activities.

The easy measuring of luciferase activity by luminoassay (Brandes et al., Neuron, 16:687-694, 1996) makes the detection of Gal4 activity comfortable in every single living fly.

Then, one of the best mode of the second or third invention, a method for gene trapping using the vector system, is described in detail.

(1) Screening:

The gene trap vector constructs can be introduced into the genome of a white minus fly by microinjection. The selection of primary transformants is possible by using G418, an analog of neomycin, resistance conferred by hs-neo gene. (When performing transformation experiments with these constructs it's turned out that the truncated mini-white gene generally provides a very slight yellow eye color which could be distinguished from w-minus phenotype in most of the cases, therefore G418 selection apparently is not necessary.)

After a line with the gene trap construct is being established, the secondary transformants can be generated on the usual way by crossing the original line with a so-called jumpstarter containing the transposase expressing delta 2-3 genetic element.

Usually a certain percentage, between 4 and 8, of the secondary transformants have much stronger eye color (deep orange or reddish) than the ancestor fly indicating that the construct was being inserted downstream of a promoter and now the mini-white gene is using the transcriptional "facilities" of that gene (e.g.: poly-adenylation site and transcriptional

terminator) instead of its removed ones. They are the most likely candidates for successful gene trap events. In case of these lines the vector probably has been inserted either into an intron of a gene or upstream from the first intron into the 5' UTR in proper orientation (that is the direction of transcription is same for the "trapped gene" and the mini-white (and Gal4) genes as well). The mini-white gene has its own promoter therefore its expression pattern is supposed to be largely independent from that of the trapped gene.

These positive lines are to be checked in the next step for Gal4 expression by crossing them with a "marker" line harboring a UAS-luciferase reporter gene construct. (When using pTrap-G4-luc vector, this step is obviously not necessary.) Usually very strong correlation was found between eye color and Gal4 expression: more than 90% of the lines having strong eye color proved to be expressing Gal4 by means of luciferase assay using luminometer (Brandes et al., Neuron, 16:687-692, 1996).

## (2) Cloning:

When the gene trap construct is being inserted into an intron of an endogenous gene, the marker genes of the construct are supposed to be spliced on mRNA level to the exons of the trapped gene by using the artificial splicing acceptor and donor sites. More exactly while the Gal4 mRNA should be joint to the exon(s) located upstream of the insertion site, at the same time the mini-white mRNA is fused to the following exon(s) accomplishing the dual tagging of the trapped gene (Figure 5).

This feature can be used for quickly and easily

identifying the trapped gene by means of 3' and 5' RACE (Rapid Amplification of cDNA Ends) experiments. Even cloning and sequencing only a part of the caught mRNA still provides reasonable chance to find homologous mRNAs in the BDGP (Berkeley Drosophila Genome Project) EST (Expressed Sequence Tag) library.

With these approaches, the identification of an already cloned gene can take less than a week compared to the usually more than one year period in average when analyzing a mutant created by some enhancer trap construct.

It's well-known from the literature and the present inventors also have experienced that P-element vectors tend to integrate into or near the 5' UTR of active genes. (The present inventors found that in these cases if the insertion occurred upstream from the first intron, and therefore the artificial splicing acceptor site could not be utilized, the Gal4 gene was expressed by read-through transcription from the nearby promoter.)

The advantage of this tendency can be taken by cloning and sequencing the flanking genomic sequences of the insertion site by inverse or vectorette PCR or by plasmid rescue using suitable restriction digestion to recover the neomycin resistance gene of the construct. Then again the BDGP library can be searched to find any significant matching.

### (3) Rescue:

The only reliable way to confirm that any observed mutant phenotype is really the consequence of the P-element insertion is to rescue that particular phenotype. Expectedly the phenotype (some alteration from wild type fly) is caused



by changed expression of gene(s) disturbed by insertion of the P-element. The rescue can be made by expressing the cDNA of the suspected gene most preferable with identical spatial and temporary pattern than that of the gene itself.

5 As it was expected, the vector constructs of the first invention usually cause strong phenotypes. It's not surprising at all because the trapped genes are supposed to be split into two parts on mRNA level resulting in null mutants in majority of the cases. Accordingly mutants  
10 obtained by this method frequently show homozygous lethality or sterility. Hypomorphic mutants can be obtained by forcing imprecise excision of the gene trap P-element construct.

As mentioned above, the Gal4 expression is obliged to reflect precisely to that of the trapped gene simply because  
15 the Gal4 gene has no its own promoter and they share a common, fused mRNA.

This identical expression provides unique opportunity to rescue the mutant phenotype by crossing this fly with another one harboring the UAS directed, cloned cDNA of the  
20 trapped gene.

On this way either the original, homozygous null mutant gene trap fly or any transheterozygous derivative of that with some hypomorphic allele over the null mutant allele can be rescued.

25

(4) Determination of spatial and developmental expression pattern of the trapped gene:

Histochemical determination of the spatially and temporarily controlled expression of any trapped gene is also  
30 easy following introduction of a UAS-lacZ construct into the

genome of the same fly and performing either X-gal or antibody staining for beta-galactosidase.

(5) Mosaic analysis:

Possession of a large collection of fly lines with  
5 different, characteristic and, in the case of the pTrap-G4-  
p53/pCasperhs-G4-TL vector system, inducible Gal4 expression  
pattern makes feasible carrying out mosaic analysis of  
virtually any gene of interest by directing the expression of  
their UAS-constructs on a mutant background with different  
10 Gal4 expression patterns.

This approach can answer the question of where and when  
that particular gene is required to be expressed to rescue  
the mutant phenotype.

Similarly, any gene can be expressed in different  
15 ectopic patterns to generate new dominant mutant phenotypes.  
This approach might help to conclude the role of that  
particular gene and to identify the pathway, in which it's  
involved.

20 **Example**

The following example illustrates a specific embodiment  
of the various aspects of the invention. This example is not  
intended to limit the invention in any manner.

Figure 6 shows the results of sequencing RT-PCR  
25 products of aop-Gal4 and m-white-aop fusion mRNAs.

The template was total RNA prepared from a positive  
gene trap line which has the vector pTrap-hsneo being  
integrated into the first intron of the well-known aop  
(anterior open/pokkuri/yan) developmental gene. The sequences  
30 confirm that both splicing occurred precisely at that

particular nucleotides of the artificial regulatory sequences where it was expected.

On Figure 7, there are pictures of characteristic beta-galactosidase staining patterns in different parts of the fly  
5 brain resulted from crossing positive gene trap lines with flies harboring a UAS-lacZ construct.

### Industrial Applicability

The vector system of this invention offers an  
10 exceptional opportunity for easy and fast cloning of the gene responsible for the observed phenotype. Furthermore, by using the UAS-driven coding sequence of any gene of interest, that particular gene can be expressed in identical patterns than those of the trapped genes and these expressions can be  
15 regulated temporarily at any desired developmental stage.

### Sequence Listing

<110> Japan Science and Technology Corporation  
<120> A Vector for Gene Trap, and A Method for Gene Trapping  
20 by Using The Vector  
<150> Japan, Application No. 10-141952  
<151> 22 May 1998  
<160> 1  
<170> PatentIn Ver. 2.0  
25 <210> 1  
<211> 11206  
<212> DNA  
<213> Artificial sequence  
<220>  
30 <221> 3' P sequence

<222> (1) .. (237)

<220>

<221> synthetic splicing acceptor site and stop/start sequence

5 <222> (238) .. (274)

<220>

<221> Gal4 gene (coding region and 3' UTR)

<222> (275) .. (3164)

<220>

10 <221> hsp70 terminator

<222> (3165) .. (3426)

<220>

<221> synthetic junction sequence

<222> 3427-3457

15 <220>

<221> heat shock promoter directed neomycine resistance gene on complement strand

<222> (3458) .. (4907)

<220>

20 <221> mini-white gene

<222> (4908) .. (8275)

<220>

<221> synthetic splicing donor site

<222> (8276) .. (8299)

25 <220>

<221> 5' P sequence

<222> (8300) .. (8446)

<220>

<221> bacterial part of pCasper3 shuttle vector including complete pUC8 sequence

30

092094-0004  
F02020-64800/60

<222> (8447) .. (11206)

<220>

<221> synthetic DNA

<222> (238) .. (274)

5 (3427) .. (3457)

(4908) .. (4914)

(8276) .. (8299)

<400> 1

	catgatgaaa taacataagg tggccccgtc ggcaagagac atccacttaa cgtatgcttg	60
10	caataagtgc gaggtaaagg aatagtatcc tgagtgtcgt attgagtctg agtgagacag	120
	cgatatgatt gttgattaac ccttagcatg tccgtgggggt ttgaattaac tcataatatt	180
	aattagacga aattatTTTT aaagTTTTat tTTtaataat ttgcgagtac gcaaagctct	240
	ttctcttaca ggtcgaattg atgtgatgga tccaatgaag ctactgtctt ctatcgaaca	300
	agcatgcgat atttgccgac ttaaaaagct caagtgtccc aaagaaaaac cgaagtgcgc	360
15	caagtgtctg aagaacaact gggagtgtcg ctactctccc aaaacaaaaa ggtctccgct	420
	gactagggca catctgacag aagtggatc aaggctagaa agactggaac agctatttct	480
	actgattttt cctcgagaag accttgacat gattttgaaa atggattctt tacaggatat	540
	aaaagcattg ttaacaggat tatttgtaca agataatgtg aataaagatg ccgtcacaga	600
	tagattggct tcagtggaga ctgatatgcc tctaacattg agacagcata gaataagtgc	660
20	gacatcatca tcggaagaga gtagtaacaa aggtcaaaga cagttgactg tatcgattga	720
	ctcggcagct catcatgata actccacaat tccgttggat tttatgcccc gggatgctct	780
	tcattgattt gattggctctg aagaggatga catgtcggat ggcttgccct tcctgaaaac	840
	ggaccccaac aataatgggt tctttggcga cggttctctc ttatgtattc ttcatctat	900
	tggctttaaa ccggaattt acacgaactc taacgttaac aggtccccga ccatgattac	960
25	ggatagatac acgttggctt ctagatccac aacatcccgt ttacttcaaa gttatctcaa	1020
	taattttcac ccctactgcc ctatcgtgca ctaccgacg ctaatgatgt tgtataataa	1080
	ccagattgaa atcgcgtcga aggatcaatg gcaaattcctt ttttaactgca tattagccat	1140
	tggagcctgg tgtatagagg gggaatctac tgatatagat gttttttact atcaaaatgc	1200
	taaatctcat ttgacgagca aggtcttcga gtcaggttcc ataattttgg tgacagccct	1260
30	acatcttctg tcgcgatata cacagtggag gcagaaaaca aatactagct ataattttca	1320

F48002683

cagcttttcc ataagaatgg ccatatcatt gggcttgaat agggacctcc cctcgtcctt 1380  
 cagtgatagc agcattctgg aacaaagacg ccgaatttgg tggctctgtct actcttggga 1440  
 gatccaattg tccctgcttt atggtcgatc catccagctt tctcagaata caatctcctt 1500  
 ccctttctct gtcgacgatg tgcagcgtac cacaacaggt cccaccatat atcatggcat 1560  
 5 cattgaaaca gcaaggctct tacaagtttt cacaaaaatc tatgaactag acaaaacagt 1620  
 aactgcagaa aaaagtccta tatgtgcaaa aaaatgcttg atgatttgta atgagattga 1680  
 ggaggtttcg agacaggcac caaagttttt acaaatggat atttccacca ccgctctaac 1740  
 caatttgttg aaggaacacc cttggctatc ctttacaaga ttogaactga agtggaacaa 1800  
 gttgtctctt atcatttatg tattaagaga ttttttcaact aattttaccc agaaaaagtc 1860  
 10 acaactagaa caggatcaaa atgatcatca aagttatgaa gttaaacgat gctccatcat 1920  
 gttaagcgat gcagcacaaa gaactgttat gtctgtaagt agctatatgg acaatcataa 1980  
 tgtcacccca ttttttgctt ggaattgttc ttattacttg ttcaatgcag tccatgtacc 2040  
 cataaagact ctactctcaa actcaaaatc gaatgctgag aataacgaga ccgcacaatt 2100  
 attacaacaa attaacactg ttctgatgct attaaaaaaa ctggccactt ttaaaatcca 2160  
 15 gacttgtgaa aaatacattc aagtactgga agaggtatgt gcgccgtttc tgttatcaca 2220  
 gtgtgcaatc ccattaccgc atatcagtta taacaatagt aatggtagcg ccattaaaaa 2280  
 tattgtcggg tctgcaacta tcgcccaata ccctactctt ccggaggaaa atgtcaacaa 2340  
 tatcagtgtt aaatatgttt ctctggctc agtagggcct tcacctgtgc cattgaaatc 2400  
 aggagcaagt ttcagtgatc tagtcaagct gttatctaac cgtccaccct ctgtaactc 2460  
 20 tccagtgaca ataccaagaa gcacaccttc gcatcgctca gtcacgcctt ttctagggca 2520  
 acagcaacag ctgcaatcat tagtgccact gaccccgctt gctttgtttg gtggcgccaa 2580  
 ttttaatcaa agtgggaata ttgctgatag ctcatgtcc ttcactttca ctaacagtag 2640  
 caacgggtccg aacctcataa caactcaaac aaattctcaa gcgctttcac aaccaattgc 2700  
 ctctctaac gttcatgata acttcatgaa taatgaaatc acggctagta aaattgatga 2760  
 25 tggtataaat tcaaaaccac tgtcacctgg ttggacggac caaactgcgt ataacgcgtt 2820  
 tggaatcact acagggatgt ttaataccac tacaatggat gatgtatata actatctatt 2880  
 cgatgatgaa gatccccac caaaccocaa aaaagagtaa aatgaatcgt agatactgaa 2940  
 aaaccccgca agttcacttc aactgtgcat cgtgcacat ctcaatttct ttcatttata 3000  
 catcgttttg ctttctttta tgtaactata ctctctaaag tttcaatctt ggccatgtaa 3060  
 30 cctctgatct atagaatttt ttaaagact agaattaatg cccatctttt ttttgacct 3120

aaattcttca tgaaaatata ttacgagggc ttattcagaa gcttatcgat accgtcgact 3180  
aaagccaaat agaaattatt cagttctggc ttaagttttt aaaagtata ttattttattt 3240  
ggttgtaacc aaccaaaga atgtaaataa ctaatacata attatgttag ttttaagtta 3300  
gcaacaaatt gattttagct atattagcta cttgggttaaat aaatagaata tattttattta 3360  
5 aagataattc gtttttattg tcaggagtg agtttgctta aaaactcgtt tagatccact 3420  
agaaggaccg cggctcctcg accggatcga aaggaggcg aagaactoca gcatgagatc 3480  
cccgcgtgg aggatcatcc agccggcgtc ccggaaaacg attccgaagc ccaacctttc 3540  
atagaaggcg gcggtggaat cgaaatctcg tgatggcagg ttgggcgtcg cttggtcggt 3600  
catttcgaac ccagagtcg cgctcagaag aactcgtcaa gaaggcgata gaaggcgatg 3660  
10 cgctgcgaat cgggagcggc gatacgtaa agcacgagga agcggtcagc ccattcgccg 3720  
ccaagctctt cagcaatatc acgggtagcc aacgctatgt cctgatagcg gtcgccaca 3780  
cccagccggc cacagtcgat gaatccagaa aagcggccat tttccaccat gatattcggc 3840  
aagcaggcat cgccatgggt cacgacgaga tcctcgccgt cgggcatgcg cgccttgagc 3900  
ctggcgaaca gttcggctgg cgcgagcccc tgatgctctt cgtccagatc atcctgatcg 3960  
15 acaagaccgg cttccatccg agtacgtgct cgctcgatgc gatgtttcgc ttggtggtcg 4020  
aatgggcagg tagccggatc aagcgtatgc agccgccgca ttgcatcagc catgatggat 4080  
actttctcgg caggagcaag gtgagatgac aggagatcct gccccggcac ttcgccaat 4140  
agcagccagt ccttcccgc ttcagtgaca acgtcgagca cagctgcgca aggaacgccc 4200  
gtcgtggcca gccacgatag ccgcgtgcc tgccttgca gttcattcag ggcaccggac 4260  
20 aggtcgtct tgacaaaaag aaccggcgcc ccctgcgtg acagccggaa cacggcggca 4320  
tcagagcagc cgattgtctg ttgtgccag tcatagcga atagcctctc caccgaagcg 4380  
gccggagaac ctgcgtgcaa tccatcttgt tcaatcatgc gaaacgatcc tcatcctgtc 4440  
tcttgatcag atcccctatt cagagttctc ttcttgatt caataattac ttcttgagc 4500  
atttcagtag ttgcagttga tttacttggg tgctggttac ttttaattga ttcacttta 4560  
25 cttgcacttt actgcagatt gtttagctg ttccagctgc cttgtttatt tgcttagctt 4620  
tcgcttagcg acgtgttcac ttgcttggt tgaattgaat tgctgctccg tagacgaagc 4680  
gcctctatct atactccggc gctcttttcg cgaacattcg aggcgcgtc tctgaacca 4740  
acgagagcag tatgccgttt actgtgtgac agagtgcagc agcattagtg cagagaggga 4800  
gagacccaaa aagaaaagag agaataacga ataacggcca gagaaatttc tcgagttttc 4860  
30 tttctgccaa acaaatgacc taccacaata accagtttgt ttgggatct agtcccta 4920



tctagtatgt atgtaagtta ataaaaccct tttttggaga atgtagattt aaaaaaacat 4980  
 attttttttt tattttttac tgcaactggac atcattgaac ttatctgac agttttaaat 5040  
 ttacttcgat ccaagggat ttgaagtacc aggttcttct gattacctct cactcaaaat 5100  
 gacattccac tcaaagtcag cgctgtttgc ctcttctct gtccacagaa atatcgccgt 5160  
 5 ctctttcgcc gctgogtccg ctatctcttt cgccaccgtt tgtagcgtta cctagcgtca 5220  
 atgtccgcct tcagttgcac tttgtcagcg gtttcgtgac gaagctcaa gcggtttacg 5280  
 ccatcaatta aacacaaagt gctgtgcaa aactcctctc gcttcttatt tttgtttgtt 5340  
 ttttgagtga ttgggggtgt gattggtttt gggtgggtaa gcaggggaaa gtgtgaaaaa 5400  
 tcccggcaat gggccaagag gatcaggagc tattaattcg cggaggcagc aaacacccat 5460  
 10 ctgccgagca tctgaacaat gtgagtagta catgtgcata catcttaagt tcacttgatc 5520  
 tataggaact gcgattgcaa catcaaattg tctgcggcgt gagaactgcg acccacaaaa 5580  
 atcccaaacc gcaatcgac aaacaaatag tgacacgaaa cagattattc tggtagctgt 5640  
 gctcgctata taagacaatt ttaagatca tatcatgac aagacatcta aaggcattca 5700  
 ttttcgacta cattcttttt tacaaaaaat ataacaacca gatattttta gctgaccta 5760  
 15 gatgcacaaa aaataaataa aagtataaac ctacttcgta ggatacttcg tttgttcgg 5820  
 ggtagatga gcataacgct ttagattgat atttgagac ccctatcatt gcagggtgac 5880  
 agcggagcgt tcgcagagct gcattaacca gggcttcggg caggccaaaa actacggcac 5940  
 gctcctgcca ccagtcgcg cggaggactc cggttcaggg agcggccaac tagccgagaa 6000  
 cctcacctat gcctggcaca atatggacat ctttggggcg gtcaatcagc cgggctccgg 6060  
 20 atggcggcag ctggtcaacc ggacacgcgg actattctgc aacgagcgac acataccggc 6120  
 gcccaggaaa catttgctca agaacgggtga gtttctattc gcagtcggct gatctgtgtg 6180  
 aaatcttaat aaagggtcca attaccaatt tgaaactcag tttgcggcgt ggcctatccg 6240  
 ggcaacttt tggccgtgat gggcagttcc ggtgccggaa agacgaccct gctgaatgcc 6300  
 cttgcctttc gatcgccgca gggcatocaa gtatcgccat ccgggatgcg actgctcaat 6360  
 25 ggccaacctg tggacgcaa ggagatgcag gccaggtgcg cctatgtcca gcaggatgac 6420  
 ctctttatcg gctccctaac ggccaggga cacctgattt tccaggccat ggtgcggatg 6480  
 ccacgacatc tgacctatcg gcagcgagtg gccgcgtgg atcaggtgat ccaggagctt 6540  
 tcgctcagca aatgtcagca cacgatcatc ggtgtgcccg gcagggtgaa aggtctgtcc 6600  
 ggcggagaaa ggaagcgtct ggcatcgcg tccgaggcac taaccgatcc gccgcttctg 6660  
 30 atctgcgatg agccacctc cggactggac tcatttaccg cccacagcgt cgtccaggtg 6720

ctgaagaagc tgtcgcagaa gggcaagacc gtcacccatga ccattcatca gccgtcttcc 6780  
 gagctgtttg agctctttga caagatcctt ctgatggccg agggcagggt agctttcttg 6840  
 ggcactccca gcgaagccgt cgacttcttt tccatgtgag ttgatgtgt ttattaaggg 6900  
 tatctagcat tacattacat ctcaactcct atccagcgtg ggtgccaggt gtcctaccaa 6960  
 5 ctacaatccg gcggactttt acgtacaggt gttggccgtt gtgcccggac gggagatcga 7020  
 gtcccgtgat cggatcgcca agatatgcga caattttgct attagcaaag tagcccggga 7080  
 tatggagcag ttgttgcca ccaaaaattt ggagaagcca ctggagcagc cggagaatgg 7140  
 gtacacctac aaggccacct ggttcatgca gttccgggcg gtccgtgggc gatccctggc 7200  
 gtcggtgctc aaggaaccac tctcgtaaa agtgcgactt attcagacaa cggtagtggt 7260  
 10 ttccagtga aacaaatgat ataacgtta caattcttg aaacaaattc gctagatttt 7320  
 agttagaatt gcctgattcc acacccttct tagttttttt caatgagatg tatagtttat 7380  
 agttttgcag aaaataaata aatttcattt aactcgcgaa catgttgaag atatgaatat 7440  
 taatgagatg cgagtaacat ttaatttgc agatggttgc catcttgatt ggccctcatc 7500  
 ttttgggcca acaactcacg caagtgggcg tgatgaatat caacggagcc atcttctct 7560  
 15 tccagacca catgacctt caaaacgtct ttgccagat aaatgtaagt cttgtttaga 7620  
 atacatttgc atattaataa ttactaact ttctaataa tcgattcgat ttaggtgttc 7680  
 acctcagagc tgccagtttt tatgaggag gcccgaaagtc gactttatcg ctgtgacaca 7740  
 tactttctgg gcaaaacgat tgccgaatta ccgcttttcc tcacagtgcc actggtcttc 7800  
 acggcgattg cctatccgat gatcggactg cgggcccggag tgctgcactt cttcaactgc 7860  
 20 ctggcgctgg tcaactctgt ggccaatgtg tcaacgtcct tcgatatct aatatcctgc 7920  
 gccagctcct cgacctcgat ggcgctgtct gtgggtccgc cggttatcat accattcctg 7980  
 ctctttggcg gcttcttctt gaactcgggc tcggtgccag tatacctcaa atggttgcg 8040  
 tacctctcat ggttccgtta cgccaacgag ggtctgtga ttaaccaatg ggcggacgtg 8100  
 gagccgggcg aaattagctg cacatcgtcg aacaccacgt gcccagttc gggcaaggtc 8160  
 25 atcctggaga cgcttaactt ctccgccgcc gatctgccgc tggactacgt gggctctggc 8220  
 attctcatcg tgagcttccg ggtgctcgca tatctggctc taagacttcg ggcccagcgc 8280  
 aaggagtaga aggtaagtag cggccgcacg taagggttaa tgttttcaaa aaaaaattcg 8340  
 tccgcacaca accttctc tcaacaagca aacgtgcact gaatttaagt gtatacttcg 8400  
 gtaagcttcg gctatcgacg ggaccacctt atgttatttc atcatgggcc agaccacgt 8460  
 30 agtccagcgg cagatcggcg gcggagaagt taagcgtctc caggatgacc ttgccgaac 8520

	tggggcacgt	ggtgttcgac	gatgtgcagc	taatttcgcc	cggctccacg	tccgccatt	8580
	ggttaatcag	cagaccctcg	ttggcgtaac	ggaaccatga	gaggtacgac	aaccatttga	8640
	ggtatactgg	cacogagccc	gagttcaaga	agaaggcggt	tttccatagg	ctccgcccc	8700
	ctgacgagca	tcacaaaaat	cgacgctcaa	gtcagagggtg	gcgaaaccog	acaggactat	8760
5	aaagatacca	ggcgtttccc	cctggaagct	ccctcgtgog	ctctcctggt	ccgaccctgc	8820
	cgcttacogg	atacctgtcc	gcctttctcc	cttcgggaag	cgtggcgctt	tctcaatgct	8880
	cacgctgtag	gtatctcagt	tcgggtgtagg	tcgttcgctc	caagctgggc	tgtgtgcacg	8940
	aaccccccg	tcagcccagc	cgctgcgcct	tatccggtaa	ctatcgtctt	gagtccaacc	9000
	cggtaagaca	cgacttatcg	ccactggcag	cagccactgg	taacaggatt	agcagagcga	9060
10	ggtatgtagg	cggtgctaca	gagttcttga	agtgggtggc	taactacggc	tacactagaa	9120
	ggacagtatt	tggtatctgc	gctctgctga	agccagttac	cttcggaaaa	agagttggta	9180
	gctcttgatc	cggcaaacaa	accaccgctg	gtagcgggtg	tttttttggt	tgcaagcagc	9240
	agattacgog	cagaaaaaaa	ggatctcaag	aagatccttt	gatcttttct	acgggggtctg	9300
	acgctcagtg	gaacgaaaac	tcacgttaag	ggatttttgt	catgagatta	tcaaaaagga	9360
15	tcttcaccta	gatcctttta	aattaaaaat	gaagttttaa	atcaatctaa	agtatatatg	9420
	agtaaacttg	gtctgacagt	taccaatgct	taatcagtga	ggcacctatc	tcagcgatct	9480
	gtctatttgc	ttcatccata	gttgccctgac	tccccgtcgt	gtagataact	acgatacggg	9540
	agggcttacc	atctggcccc	agtgtctcaa	tgataccgog	agacccacgc	tcaccggctc	9600
	cagatttatc	agcaataaac	cagccagccg	gaaggggcca	gcgcagaagt	ggtcctgcaa	9660
20	ctttatccgc	ctccatccag	tctattaatt	gttgccggga	agctagagta	agtagttcgc	9720
	cagttaatag	tttgcgcaac	gttggttgcca	ttgctacagg	catcgtgggtg	tcacgctcgt	9780
	cgtttgggtat	ggcttcattc	agctccgggt	cccaacgata	aaggcgaggt	acatgatccc	9840
	ccatgttggtg	caaaaaagcg	gttagctcct	toggctcctc	gatcgttgct	agaagtaagt	9900
	tggccgcag	gttatcactc	atgggttatgg	cagcactgca	taattctctt	actgtcatgc	9960
25	catccgtaag	atgcttttct	gtgactgggtg	agtactcaac	caagtcattc	tgagaatagt	10020
	gtatgcggcg	accgagttgc	tcttgcccgg	cgtcaacacg	ggataatacc	gcgccacata	10080
	gcagaacttt	aaaagtgtc	atcattggaa	aacgtttctc	ggggcgaaaa	ctctcaagga	10140
	tcttaccgct	gttgagatcc	agttcgatgt	aaccactcog	tgacaccaac	tgatcttcag	10200
	catcttttac	tttcaccagc	gtttctgggt	gagcaaaaac	aggaaggcaa	aatgccgcaa	10260
30	aaaagggaat	aaggggcgaca	cggaaatgtt	gaatactcat	actcttctct	tttcaatatt	10320

attgaagcat	ttatcagggt	tattgtctca	tgagcggata	catatttgaa	tgtatttaga	10380
aaaataaaca	aataggggtt	ccgcgcacat	ttccccgaaa	agtgccacct	gacgtctaag	10440
aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	tatcacgagg	ccctttcgtc	10500
tgcgcggttt	cggatgatgac	ggtgaaaacc	tctgacacat	gcagctcccg	gagacgggtca	10560
cagcttgtct	gtaagcggat	gccggggagca	gacaagcccg	tcagggcgcg	tcagcgggtg	10620
ttggcgggtg	tcgggggtgg	cttaactatg	cggcatcaga	gcagattgta	ctgagagtgc	10680
accatatgcg	gtgtgaaata	ccgcaccgaa	tcgcgcggaa	ctaacgacag	tcgctccaag	10740
gtcgtcgaac	aaaaggtgaa	tgtgttgccg	agagcgggtg	ggagacagcg	aaagagcaac	10800
tacgaaacgt	ggtgtggtgg	aggtgaatta	tgaagagggc	gcgcgatttg	aaaagtatgt	10860
atataaaaaa	tatatcccgg	tgttttatgt	agcgataaac	gagtttttga	tgtaaggtat	10920
gcaggtgtgt	aagtcttttg	gtagaagac	aaatccaaag	tctacttggtg	gggatgttcg	10980
aaggggaaat	acttgtattc	tataggtcat	atcttgtttt	tattggcaca	aatataatta	11040
cattagcttt	ttgagggggc	aataaacagt	aaacacgatg	gtaataatgg	taaaaaaaaaa	11100
aacaagcagt	tatttcggat	atatgtcggc	tactccttgc	gtcgggccccg	aagtottaga	11160
gccagatatg	cgagcaccgc	gaagctcacg	atgagaatgg	ccagac		11206

## CLAIMS

1. A vector for trapping an unknown gene of *Drosophila melanogaster*, which is a recombinant plasmid comprising the  
5 following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

a reporter gene;

a drug resistance gene;

10 a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site.

2. The vector of claim 1, wherein the recombinant plasmid  
15 is derived from pCasper3.

3. The vector of claim 1 or 2, wherein the reporter gene is the Gal4 gene.

20 4. The vector of claim 3, which has the nucleotide sequence of SEQ ID No. 1.

5. The vector of claim 1 or 2, wherein the reporter gene is Gal4 DNA binding domain-P53 fusion gene.

25 6. The vector of claim 1 or 2, wherein the reporter gene is the Gal4-firefly luciferase fusion gene.

7. The vector of any one of claims 1-6, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene.  
30

8. The vector of any one of claims 1-7, wherein the drug resistance gene is neomycin-phosphotransferase gene and its promoter is a heatshock promoter.

5

9 A vector derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs.

10 10. A method for trapping an unknown gene of *Drosophila melanogaster* by using a vector which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

a synthetic "stop/start" sequence;

15 a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

a synthetic splicing donor site,

20 which method comprises the steps of:

(a) introducing the vector into the genome of a white minus fly;

(b) selecting primary transformants resistant to a drug;

(c) crossing the primary transformants with a transposase source strain to force the vector to jump into other locations;

(d) selecting secondary transformants by picking up the flies having strong eye color,

(e) crossing the secondary transformants with UAS (Upstream Activator Sequence)-luciferase harboring strain and measuring

30

the reporter gene expression of the resultant flies; and

(f) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

5

11. The method according to claim 10, wherein the recombinant plasmid is derived from pCasper3.

10 12. The method according to claim 10 or 11, wherein the reporter gene in the vector is the Gal4 gene, and in the step (e) the Gal4 expression is measured.

15 13. The method according to claim 10 or 11, wherein the reporter gene of the vector is the Gal4-firefly luciferase fusion gene, and in the step (e) expression of said fusion gene is measured without crossing the secondary transformants with UAS-luciferase harboring strain.

20 14. The method according to any one of claims 10 to 14, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene, and in the step (f) the cDNAs fused to the reporter gene and the mini-white gene are cloned and sequenced.

25 15. The method according to any one of claims 10 to 15, wherein the drug resistance gene is neomycin-phosphotransferase gene and its promoter is a heatshock promoter, and in the step (b) the transformants resistant to G418 is selected.

30 16. A method for trapping an unknown gene of *Drosophila*



*melanogaster* by using a vector A which is a recombinant plasmid comprising the following nucleotide sequences in this order:

an artificial consensus splicing acceptor site;

5 a synthetic "stop/start" sequence;

Gal4 DNA binding domain-P53 fusion gene as a reporter gene;

a drug resistance gene;

a gene responsible for a detectable phenotype of the *Drosophila melanogaster*; and

10 a synthetic splicing donor site,

and a vector B derived from pCasperhs, which has the heatshock promoter directed Gal4 activator domain-large T antigen fusion gene within polycloning site of the pCasperhs,

which method comprises the steps of:

15 (a) introducing each of the vectors A and B into the genomes of separate white minus flies;

(b) selecting primary transformants for the vector A which are resistant to a drug, and selecting primary transformants for the vector B which have an eye color;

20 (c) crossing the primary transformants for the vector A with a transposase source strain to force the vector to jump into other locations;

(d) selecting secondary transformants for the vector A by picking up the flies having strong eye color;

25 (e) crossing the secondary transformants with the primary transformants for the vector B to obtain flies harboring both the vectors A and B;

(f) crossing the flies obtained in the step (e) with an UAS-luciferase harboring fly strain and measuring the  
30 reporter gene expression of the resultant flies after a

heatshock treatment; and

(g) identifying the trapped gene by cloning and sequencing the cDNAs fused to the reporter gene and the gene responsible for a detectable phenotype of the fly.

5


17. The method according to claim 16, wherein the vector A is derived from pCasper3.

10 18. The method according to claim 16 or 17, wherein the gene responsible for a detectable phenotype of the *Drosophila melanogaster* is mini-white gene, and in the step (g) the cDNAs fused to the reporter gene and the mini-white gene are cloned and sequenced.

15 19. The method according to any one of claims 16 to 18, wherein the drug resistance gene is neomycin-phosphotransferase gene and its promoter is a heatshock promoter, and in the step (b) the transformant resistant to G418 is selected.


1/7

Fig. 1




2/7

Fig. 2




3/7

Fig. 3



4/7


Fig. 4



T02020-04800600

5/7

Fig. 5





6/7

Fig. 6

Precise splicing of Gal4 and mini-white genes from Gene Trap vector  
into anterior open gene


5'P end of vector; splice acceptor site/stop-start seq./Gal4 gene.....mini-white gene/splice donor site; 3'P end of GT vector  
.....tttggcgtatgcgaagctcttctcttaacg/gtcgaattgatgtgatgcatacctaatgagct.....agacttcggttcccgatgcgaagggtagag/gtaagttagctggccgacgttaagggttaattg.....

anterior open cDNA      exon 1      exon 2  
cagtacgtaaccacagtgccacagtgagcaaacag/ataacacggcttaaaagcaattccagtggttcac

anterior open exon 1 - Gal4 fusion cDNA  
cagtagtaaccacagtcacagtcgagcnaacag/gtcgaattgattgtgattgtaacattgagct

mini-white - anterior open exon 2 fusion cDNA  
agacttctgggttcgcgcagaggtatgaag/ataacacgcgcttaaaagcaattccagtggtcttcac

Fig. 7



## DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original    () Supplemental    () Substitute    (X) PCT    () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. NEW, filed November 21, 2000, and with amendments through (if applicable), or

(X) the specification in International Application No. PCT/JP99/02683, filed May 21, 1999, and as amended on (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	141952/1998	May 22, 1998	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., jointly and severally, attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from NISHIZAWA & ASSOCIATES as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.  
2033 K Street, N.W., Suite 800  
Washington, D.C. 20006

WENDEROTH, LIND & PONACK, L.L.P.  
Area Code (202) 721-8200

Direct Facsimile Messages to:

Area Code (202) 721-8250

Full Name of First Inventor	FAMILY NAME LUKACSOVICH	FIRST GIVEN NAME Tamas	SECOND GIVEN NAME
Residence & Citizenship	CITY Tokyo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Hungary
Post Office Address	ADDRESS 2-30-13, Narusedai, Machida-shi, Tokyo, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Second Inventor	FAMILY NAME ASZTALOS	FIRST GIVEN NAME Zoltan	SECOND GIVEN NAME
Residence & Citizenship	CITY Tokyo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Hungary
Post Office Address	ADDRESS 3-16-21, Narusedai, Machida-shi, Tokyo, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Third Inventor	FAMILY NAME YAMAMOTO	FIRST GIVEN NAME Daisuke	SECOND GIVEN NAME
Residence & Citizenship	CITY Tokyo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 4-18-8, Narusedai, Machida-shi, Tokyo, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fourth Inventor	FAMILY NAME AWANO	FIRST GIVEN NAME Wakae	SECOND GIVEN NAME
Residence & Citizenship	CITY Kanagawa	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS Famiyu-102, 3-10-12, Minamidai, Sagamihara-shi, Kanagawa, Japan	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Tamas Lukacsovich Date January 1, 2001  
Tamas LUKACSOVICH

2nd Inventor Zoltan Asztalos Date January 1, 2001  
Zoltan ASZTALOS

3rd Inventor Daisuke Yamamoto Date January 1, 2001  
Daisuke YAMAMOTO

4th Inventor Wakae Awano Date January 1, 2001  
Wakae AWANO

5th Inventor \_\_\_\_\_ Date \_\_\_\_\_

6th Inventor \_\_\_\_\_ Date \_\_\_\_\_

The above application may be more particularly identified as follows:

U.S. Application Serial No. NEW Filing Date November 21, 2000

Applicant Reference Number 99-F-032/PCT-US/YS Atty Docket No. 2000-1561A

Title of Invention A VECTOR FOR GENE TRAP, AND A METHOD FOR GENE TRAPPING BY USING THE VECTOR